Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models.
Elliott, M., Favre-Guilmard, C., Liu, S.M., Maignel, J., Masuyer, G., Beard, M., Boone, C., Carre, D., Kalinichev, M., Lezmi, S., Mir, I., Nicoleau, C., Palan, S., Perier, C., Raban, E., Zhang, S., Dong, M., Stenmark, P., Krupp, J.(2019) Sci Adv 5: eaau7196-eaau7196
- PubMed: 30746458 
- DOI: 10.1126/sciadv.aau7196
- Primary Citation of Related Structures:  
6G5G, 6G5F, 6G5K - PubMed Abstract: 
Although botulinum neurotoxin serotype A (BoNT/A) products are common treatments for various disorders, there is only one commercial BoNT/B product, whose low potency, likely stemming from low affinity toward its human receptor synaptotagmin 2 (hSyt2), h ...